🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in France / NCT05433077
Active, not recruiting Observational

Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment

NCT05433077 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2022-06-27
Last updated
2025-08-26

Condition(s) studied

Non-Metastatic Breast CarcinomaRemissionQuality of Life

Study summary

The PACThe - Real life project is a post-therapeutic support and rehabilitation for women in complete remission of breast cancer in a thermal environment. It consists of a 3 weeks spa treatment for patients in remission of breast cancer. This stay in spa treatment will be an adapted "post-cancer" support and has the main objective of showing a lasting improvement in the quality of life following the program offered to women following their breast cancer treatments.

The evaluation of the quality of life will be done using the SF-36 self-questionnaire which will be completed by the patients 5 times (inclusion visit, end of the spa stay, 6 months post-cure, 12 months post-cure and 18 months post-cure).

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Patient suffering from breast cancer * Treated by chemotherapy and/or radiotherapy * Absence of residual or progressive disease * Patient whose treatment has ended (except hormone therapy) * Able to give informed consent to participate in research * Affiliation to a Social Security scheme Exclusion Criteria: * Cancer in progressive or metastatic phase * Disabled patient * Serious personality or eating behavior disorders (craving, bulimia, etc.) * Thinness (BMI \< 18.5 kg.m-2) * Severe to massive obesity (BMI \> 35 kg.m-2) * Refusal to participate * Contraindication to physical activity (of cardiovascular origin or linked to a pathology of the musculoskeletal system), lymphedema is not a contraindication * Participation in another clinical study * Insufficient knowledge or understanding of the French language making it impossible to correctly complete a self-administered quality of life questionnaire or to answer a dietary questionnaire * The medical contraindications of spa treatment validated by the French Society of Hydrology and Climatology will be applied and are as follows: * Severe alterations in general condition (evolving infectious state, renal or hepatic insufficiency, cirrhosis, respiratory insufficiency, etc.) * Severe or acute ulcerative colitis and Crohn's disease * Severe immunodeficiencies * Recent phlebitis * Hypertension

Primary outcome measure(s)

Trial sites (15)

FacilityCityRegionStatus
Thermes de Balaruc-les-Bains Balaruc-les-Bains France
Thermes de Barbotan Barbotan-les-Thermes France
Thermes de Cambo-les-Bains Cambo-les-Bains France
Thermes de Capvern-les-Bains Capvern France
Thermes de Contrexéville Contrexéville France
Bains de Sarrailh Dax France
Thermes d'Eugénie-les-Bains Eugénie-les-Bains France
Thermes de Gréoux-les-Bains Gréoux-les-Bains France
Thermes de La Léchère La Léchère France
Thermes de la Roche-Posay La Roche-Posay France
Thermes de Luxeuil-les-Bains Luxeuil-les-Bains France
Thermes de Molitg-les-Bains Molitg-les-Bains France
Thermes de Saint Amand-les-Eaux Saint-Amand-les-Eaux France
Thermes de Soucéo Saint-Paul-lès-Dax France
Thermes de Saujon Saujon France

More Centre Jean Perrin trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05433077 on ClinicalTrials.gov ↗ ← All trials in France